Can positive psychology calm an irritable gut?

Irritable bowel syndrome is common, and behavioural approaches known as brain-gut behaviour therapies are among the better-supported options, but they are not always acceptable or easy to scale. Positive psychology interventions, which deliberately cultivate wellbeing rather than only reducing distress, have been linked to improved health outcomes in a range of medical populations, yet they had not been investigated in irritable bowel syndrome. That leaves an open question about whether a wellbeing-focused approach can shift gut symptoms, and if so through what physiological route. Registering a protocol before results exist also lets readers see what was planned rather than only what turned out well.

The WISH 2.0 trial is a parallel-group pilot randomised controlled trial that aims to enrol 50 adults meeting Rome IV criteria for irritable bowel syndrome. Participants are randomised one to one, stratified by IBS subtype and gender, to either the nine-week positive psychology intervention or a time- and attention-matched educational control. Both arms involve nine weekly 30-minute phone sessions with accompanying manualised weekly exercises. Primary outcomes are feasibility, defined as the proportion completing at least six of the nine sessions, and acceptability from weekly ease and utility ratings. Assessments occur at baseline, midpoint, post-intervention and three months later.

There are no outcome results yet: this publication reports the trial's design and status only. The trial was approved by the Mass General Brigham Institutional Review Board and prospectively registered in March 2025, with funding awarded in June 2025 and recruitment beginning in October 2025. As of July 2026, 20 participants had been enrolled, and study completion is anticipated in August 2028. Alongside symptom, health-behaviour and psychological outcomes, the team plans to explore candidate gut-brain mechanisms: autonomic function via heart rate variability, interoception by self-report, gene expression by whole transcriptome RNA sequencing, and immune activity via serum inflammatory biomarkers.

This extends a literature in which positive psychology has been applied to other medical conditions but not to irritable bowel syndrome, and it sits within the growing field of brain-gut behaviour therapies. By using an attention-matched educational control, the design tries to separate any benefit of the wellbeing content from the benefit of simply having weekly contact with a clinician. The authors explicitly note that equivalent outcomes between arms are a possible result and would still be informative. Because it is a pilot focused on feasibility and acceptability, it will not settle whether the intervention works; that would require the fully powered efficacy trial it is designed to inform.

For anyone living with irritable bowel syndrome, this is a signal of where research is heading rather than something to act on: the psychological and physiological pathways between brain and gut are being tested formally, including with objective measures such as heart rate variability and inflammatory markers. It is worth knowing that a phone-delivered format is being trialled precisely because scalability and acceptability are barriers to existing therapies. Nothing here tells you whether cultivating positive wellbeing eases gut symptoms; the trial has not reported. Reading protocols like this is mainly useful as a check against later selective reporting.